Drug delivery systems for photodynamic therapy

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 1, 2009, Pages 1-7

  Donnelly, Ryan F ^a   McCarron, Paul A ^b   Woolfson, David ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Age related macular degeneration; Cancer; Drug delivery; Microbial infection; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; BEVACIZUMAB; CARBOMER; EUDRAGIT; NOVEON; PEGAPTANIB; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; POLOXAMER; PORPHYRIN DERIVATIVE; RANIBIZUMAB; TEMOPORFIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VERTEPORFIN; DRUG CARRIER;

ACTINIC KERATOSIS; ANTIMICROBIAL ACTIVITY; ARTICLE; AWARENESS; BASAL CELL CARCINOMA; BLADDER TUMOR; BLOOD VESSEL PERMEABILITY; BOWEN DISEASE; CELL DESTRUCTION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SELECTIVITY; ENZYME ACTIVITY; ERADICATION THERAPY; FEMALE GENITAL TRACT TUMOR; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; IRRADIATION; LASER; LUNG CANCER; MOLECULAR WEIGHT; MOUTH TUMOR; NECK CANCER; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PAGET SKIN DISEASE; PATENT; PHOTODYNAMIC THERAPY; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SKIN DEFECT; SKIN TUMOR; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VISUAL ACUITY; DRUG DESIGN; DRUG INDUSTRY; METHODOLOGY; PHOTOCHEMOTHERAPY; REVIEW; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PATENTS AS TOPIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN ABSORPTION;

EID: 60849112840     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109787158319     Document Type: Article

References (61)

1. Gannon MJ, Brown SB. Photodynamic therapy and its applications in gynaecology. Br J Obstet Gynae 1999; 106: 1246-1254.
2. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research. Photochem Photobiol 1997; 65: 235-251.
3. De Rosa FS, Bentley MVLB. Photodynamic therapy of skin cancers: Sensitizers, clinical studies and future directives. Pharmaceut Res 2000; 17: 1447-1455.
4. Fritsch C, Lang K, Neuse W, Ruzicka T, Lehmann P. Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol App Skin Physiol 1998; 11: 358-373.
5. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Amer. Acad Dermatol 2000; 42: 389-413.
6. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B Biol 2002; 66: 89-106.
7. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Nat Cancer Inst 1998; 90: 889-905.
8. Kalyanasundaram K. Photochemistry of Polypyridine and Porphyrin Complexes. Academic Press, London 1992.
9. Isaacs NS. Physical organic chemistry. Longman Scientific and Technical, Essex 1992.
10. Oschner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B Biol 1997; 39: 1-18.
11. Moan J, Streckyte G, Bagdonas S, Bech O, Berg K. Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Int J Cancer 1997; 70: 90-97.
12. Moan J. On the diffusion length of singlet oxygen in cells and tissues. J Photochem Photobiol B Biol 1990: 6, 343-347.
13. Gantchev TG, Brasseur N, Van Lier JE. Combination toxicity of etoposide (VP-16) and photosensitisation with water-soluble aluminium phthalocyanine in K562 human leukaemic cells. Br J Cancer 1996; 74: 1570-1577.
14. Kessel, D. Transport and localisation of m-THPC in vitro. Int J Clinical Pract 1999; 53: 263-267.
15. Pottier R, Kennedy JC. New trends in photobiology. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B Biol 1990; 8: 1-16.
16. Jori G, Beltramini M, Reddi E, et al. Evidence for a major role of plasma lipoproteins as haematoporphyrin carriers in vivo. Cancer Lett 1984; 24: 291-297.
17. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient and metabolic microenvironment and human tumour. Cancer Res 1989; 49: 6449-6465.
18. Costa R, Farah A, Cardillo ME, Belfort JA. Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age-related macular degeneration. Curr Eye Res 2001; 23: 271-275.
19. Koh AHC, Ang CL. Age-related macular degeneration: What's new? Annals- Acad Med Singapore 2002; 31: 399-404.
20. Robinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolevulinic acid photodynamic therapy. Acta Dermatol Venereol 1999; 79: 451-455.
21. Schick E, Ruck A, Boehncke W-H., Kaufmann R. Topical photodynamic therapy using methylene blue and 5-aminolevulinic acid in psoriasis. J Dermatologic Treat 1997; 8: 17-19.
22. Wainwright M. Photodynamic antimicrobial chemotherapy. J Antimicrob Chemotherapy 1998; 42: 13-28.
23. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principals and present clinical experience. J Photochem Photobiol B Biol 1990; 6: 143-148.
24. Meijnders PJN, Star WM, De Bruijn RS, et al. Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5-aminolevulinic acid. Lasers Med Sci 1996; 11: 123-131.
25. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): Mechanisms and clinical results. J Clinic Laser Med Surgery 1996; 14: 289-304.
26. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX: A clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B Biol 1992; 14: 275-292.
27. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997; 79: 2282-2308.
28. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolevulinic acid-treated cells. Br J Cancer 1996; 74: 688-697.
29. Rittenhouse-Diakun K, Van Leengoed H, Morgan J. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol 1995; 61: 523-528.
30. Bottomley S, Muller-Eberhard U. Pathophysiology of heme synthesis. Sem Heme Synth 1988; 25: 282-302.
31. Moan J, Berg K, Gadmar O, Iani V, Ma LW, Juzenas P. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem Photobiol 1999; 70: 669-673.
32. Moan J, Van den Akker JTHM, Juzenas P, et al. On the basis for tumor selectivity in the 5-aminolevulinic acid-induced synthesis of protoporphyrin IX. J Porphyrins Phthalocyanines 2001; 5: 170-176.
33. Krieg RC, Messmann H, Rauch J, Seeger S, Knuechel, R. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 2002; 76: 518-525.
34. Gibson SL, Havens JJ, Metz L, Hilf R. Is delta-aminolevulinic acid dehydratase rate limiting in heme biosynthesis following exposure of cells to delta-aminolevulinic acid? Photochem Photobiol 2001; 73: 312-317.
35. Krieg RC, Fickweiler S, Appel S, Wolfbeis OS, Knuechel R. Celltype specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000; 72: 226-233.
36. Govil SK. Transdermal drug delivery systems. In Drug Delivery Devices (Edited by P. Tyle), Chapter 3. Marcel Dekker, New York 1988.
37. Jin ZH, Miyoshi N, Ishiguro K, et al. Photodynamic therapy based on combined use of 5-aminolevulinic acid with a pheophoride-a derivative for murine tumors. In vivo 2000; 14: 529-534.
38. Wong TW, Aizawa K, Sheyhedin I, Wushur C, Kato H. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): Implication of topical NPe6-photodynamic therapy. J Pharmacol Sci 2003; 93: 136-142.
39. Donnelly RF, McCarron PA, Morrow DIJ, Sibani SA, Woolfson AD. Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms. Expert Opin Drug Del 2008; 5: 757-766.
40. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clinical Pharmacol 2002; 42: 547-557.
41. La Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration. Drugs and Aging 2002; 19: 101-133.
42. www.dusapharma.com. Accessed 16th August 2008.
43. www.photocure.no. Accessed 16th August 2008.
44. www.novartis.com. Accessed 16th August 2008.
45. www.qltinc.com. Accessed 20th August 2008.
46. www.biolitecpharma.com. Accessed 21st August 2008.
47. Lee, G., Sziemies, R.M., Kosciessa, U.: EP1467706 B1 (2007).
48. Lee, G., Sziemies, R.M., Kosciessa, U.: WO2006061621 (2006).
49. Mantelle, J.A., Golub, A.L.: WO0010879 (1996).
50. Tsui-Min, T.: US20040009212 A1 (2004).
51. Mayoral, F.: US20060182790 A1 (2006).
52. Meserol, P.M.: US5474528 A (1995).
53. Neuberger, W., Spaniol, S., Bode, H.P., Patrice, P., Bourre, L.: US20030028227 A1 (2003).
54. Taylor, K., Mesaros, J.: WO100478 A2 (2002).
55. Love, W.G., Cook, M.J., Russell, D.A.: US20036630128B1 (2003).
56. Love, W.G., Brundish, D., Rhys-Williams, D., Feng, X.D., Pugin, B.: US20077244841 B2 (2007).
57. www.destinypharma.com. Accessed 30th August 2008.
58. Vogel, E., Richert, C., Benninghaus, M.M., Cross, A.D.: US5409900 (1995).
59. Taylor, P.W., Love, W.G., van der Zanden, B.C.H.: US5616602 (1997).
60. Brown, S.B., O'Grady, C.C., Griffiths, J., Mellish, K.J., Vernon, D.I.: US20087371744 B2 (2008).
61. www.photopharmica.com. Accessed 30th August 2008.